Doximity’s 2025 Physician Compensation Report shows only modest pay growth but widening disparities across gender, pediatric vs. adult specialties, and practice settings. Gastroenterologists averaged $537,870, ranking 13th overall. Despite rising burnout and overwork, most physicians would still choose the profession—though many consider leaving or scaling back. The findings highlight systemic inequities, with AGA leaders calling for stronger gender equity initiatives.
Author: Abhay Panchal
At least 47% of physicians were employed by or affiliated with hospital systems in 2024, up from around 30% in 2012, according to a new Government Accountability Office report. Here are five GI trends from the report: 1. Private equity roll-ups are shaping GI. One firm grew a GI network from 110 to 400+ sites in four years, reaching a $2.2 billion valuation before physicians bought back ownership with new PE support. 2. Market concentration is rising. In some metro areas, private equity firms employ over 30% of gastroenterologists, often with a single firm dominating local market share.
A new analysis has revealed striking cost disparities tied to physician practice affiliation. For the same high-volume procedures across cardiology, gastroenterology, orthopedics, and urology, hospital outpatient departments emerged as the most expensive sites of care—sometimes exceeding costs in ambulatory surgery centers or physician offices by over 1,000%. Independent and private equity-affiliated physicians were far more likely to treat patients in lower-cost settings, while hospital-based doctors consistently gravitated toward higher-cost environments.
Omada Health has introduced Meal Map, a nutrient-categorization tool that blends AI feedback with human care support to help patients build sustainable eating habits. Unlike restrictive diets, the platform emphasizes nutrient density — boosting immunity, energy, digestive health, and reducing risks of cardiovascular disease, diabetes, and cancer. A pilot with 1,000+ members showed higher engagement, with instant meal analysis and weekly nutrition progress reports. Positioned within Omada’s “Nutritional Intelligence” suite, it aligns with the surge in GLP-1 use and demand for long-term, food-freedom strategies.
This week’s OncoDaily GI curation spans some of the most exciting fronts in gastrointestinal oncology: Each post features insights from global leaders — from Francesc Balaguer to Catherine Alix-Panabières — offering a window into how prevention, precision medicine, and equity are reshaping GI cancer care.
Optum-owned SCA Health, one of the nation’s largest ASC operators, based in Deerfield, Ill., continues to grow its gastroenterology footprint and strengthen its physician partnerships in 2025. Here are 10 things to know so far in 2025:
Gastroenterology is facing workforce shortages, reimbursement cuts and private equity growth in 2025, while top ASCs continue to gain national recognition. Here are seven numbers to know so far this year: . . .
The White House has unveiled “TrumpRx,” a government-run website that will allow Americans to buy prescription drugs directly from manufacturers. Pfizer is the first to sign on, agreeing to sell all of its drugs at reduced “most favored nation” prices to Medicaid and on TrumpRx. In exchange, the company secures a three-year exemption from national-security-related tariffs, provided it invests in U.S. manufacturing. The deal marks a major shift in drug pricing strategy—one Trump says will set the tone for future pharma negotiations.
A major UK trial is testing whether computer-assisted detection (CADe) truly transforms colonoscopy outcomes in everyday practice. Interim results from the NAIAD study—spanning 29 hospitals and 124 endoscopists—show CADe boosts adenoma detection rates, especially for nonexpert endoscopists, lifting ADR from under 20% to around 35%. But the effect vanishes once the system is switched off, raising questions about overreliance and whether the technology builds lasting skill. Experts caution that while CADe offers an immediate lift, its benefits may be more fragile than hoped—highlighting both the promise and the pitfalls of AI in endoscopy.
The FDA has approved guselkumab (Tremfya, J&J) as the first IL-23 inhibitor available in both subcutaneous (SC) and IV induction regimens for moderate to severe ulcerative colitis. Results from the phase 3 ASTRO trial showed significant improvements in remission and endoscopic outcomes with SC dosing, comparable to IV induction. Experts note the SC route could ease barriers by enabling self-administration and reducing infusion burdens.